The versatile role of gliadin peptides in celiac disease

Clinical Biochemistry

Volumn 46, Issue 6, 2013, Pages 552-560

  De Re, Valli ^a   Caggiari, Laura ^a   Tabuso, Maria ^a   Cannizzaro, Renato ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Celiac disease; Endosome; Gliadin; Immune response

Indexed keywords

AUTOANTIBODY; GLIADIN; GLUTEN; PEPTIDE;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; CELIAC DISEASE; CELL PROLIFERATION; CLINICAL FEATURE; DISEASE ASSOCIATION; ENDOSOME; ENVIRONMENTAL FACTOR; GLUTEN FREE DIET; HEREDITY; HLA SYSTEM; HUMAN; INNATE IMMUNITY; INTESTINE CELL; INTESTINE EPITHELIUM; INTRACELLULAR SPACE; LYMPHOCYTIC INFILTRATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE; GENETICS; IMMUNOLOGY; METABOLISM;

AUTOANTIBODIES; CELIAC DISEASE; CELL PROLIFERATION; ENDOSOMES; GLIADIN; GLUTENS; HUMANS; IMMUNITY, INNATE; PEPTIDES; T-LYMPHOCYTES;

EID: 84891721240     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.10.038     Document Type: Review

References (90)

1. Dube C., Rostom A., Sy R., Cranney A., Saloojee N., Garritty C., et al. The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review. Gastroenterology 2005, 128:S57-S67.
2. Biagi F., Klersy C., Balduzzi D., Corazza G.R. Are we not over-estimating the prevalence of coeliac disease in the general population?. Ann Med 2010, 42:557-561.
3. Di Sabatino A., Corazza G.R. Coeliac disease. Lancet 2009, 373:1480-1493.
4. Meresse B., Malamut G., Cerf-Bensussan N. Celiac disease: an immunological jigsaw. Immunity 2012, 36:907-919.
5. Oberhuber G., Granditsch G., Vogelsang H. The histopathology of coeliac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol 1999, 11:1185-1194.
6. Malamut G., Meresse B., Cellier C., Cerf-Bensussan N. Refractory celiac disease: from bench to bedside. Semin Immunopathol 2012, 34:601-613.
7. Malamut G., Afchain P., Verkarre V., Lecomte T., Amiot A., Damotte D., et al. Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology 2009, 136:81-90.
8. Chandesris M.O., Malamut G., Verkarre V., Meresse B., Macintyre E., Delarue R., et al. Enteropathy-associated T-cell lymphoma: a review on clinical presentation, diagnosis, therapeutic strategies and perspectives. Gastroenterol Clin Biol 2010, 34:590-605.
9. Ho-Yen C., Chang F., van der W.J., Mitchell T., Ciclitira P. Recent advances in refractory coeliac disease: a review. Histopathology 2009, 54:783-795.
10. Biagi F., Corazza G.R. Mortality in celiac disease. Nat Rev Gastroenterol Hepatol 2010, 7:158-162.
11. Malamut G., Verkarre V., Callens C., Colussi O., Rahmi G., Macintyre E., et al. Enteropathy-associated T-cell lymphoma complicating an autoimmune enteropathy. Gastroenterology 2012, 142:726-729.
12. Di Sabatino A., Biagi F., Gobbi P.G., Corazza G.R. How I treat enteropathy-associated T-cell lymphoma. Blood 2012, 119:2458-2468.
13. Molberg O., Kett K., Scott H., Thorsby E., Sollid L.M., Lundin K.E. Gliadin specific, HLA DQ2-restricted T cells are commonly found in small intestinal biopsies from coeliac disease patients, but not from controls. Scand J Immunol 1997, 46:103-109.
14. Medrano L.M., Garcia-Magariños M., Dema B., Espino L., Maluenda C., Polanco I., et al. Th17-related genes and celiac disease susceptibility. PLoS One 2012, 7.
15. Fernandez S., Molina I.J., Romero P., Gonzalez R., Pena J., Sanchez F., et al. Characterization of gliadin-specific Th17 cells from the mucosa of celiac disease patients. Am J Gastroenterol 2011, 106:528-538.
16. Bodd M., Raki M., Tollefsen S., Fallang L.E., Bergseng E., Lundin K.E., et al. HLA-DQ2-restricted gluten-reactive T cells produce IL-21 but not IL-17 or IL-22. Mucosal Immunol 2010, 3:594-601.
17. Malamut G., El Machhour R., Montcuquet N., Martin-Lanneree S., Dusanter-Fourt I., Verkarre V., et al. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. J Clin Invest 2010, 120:2131-2143.
18. Bulfone-Paus S., Ungureanu D., Pohl T., Lindner G., Paus R., Ruckert R., et al. Interleukin-15 protects from lethal apoptosis in vivo. Nat Med 1997, 3:1124-1128.
19. Waldmann T.A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006, 6:595-601.
20. Depaolo R.W., Abadie V., Tang F., Fehlner-Peach H., Hall J.A., Wang W., et al. Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens. Nature 2011, 471:220-225.
21. Yokoyama S., Watanabe N., Sato N., Perera P.Y., Filkoski L., Tanaka T., et al. Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes. Proc Natl Acad Sci U S A 2009, 106:15849-15854.
22. Ang S., Kogulanathan J., Morris G.A., Kok M.S., Shewry P.R., Tatham A.S., et al. Structure and heterogeneity of gliadin: a hydrodynamic evaluation. Eur Biophys J 2010, 39:255-261.
23. Fleckenstein B., Molberg O., Qiao S.W., Schmid D.G., von der M.F., Elgstoen K., et al. Gliadin T cell epitope selection by tissue transglutaminase in celiac disease. Role of enzyme specificity and pH influence on the transamidation versus deamidation process. J Biol Chem 2002, 277:34109-34116.
24. Shan L., Molberg O., Parrot I., Hausch F., Filiz F., Gray G.M., et al. Structural basis for gluten intolerance in celiac sprue. Science 2002, 297:2275-2279.
25. Sturgess R., Day P., Ellis H.J., Lundin K.E., Gjertsen H.A., Kontakou M., et al. Wheat peptide challenge in coeliac disease. Lancet 1994, 343:758-761.
26. Picarelli A., Di Tola M., Sabbatella L., Anania M.C., Di Cello T., Greco R., et al. 31-43 Amino acid sequence of the alpha-gliadin induces anti-endomysial antibody production during in vitro challenge. Scand J Gastroenterol 1999, 34:1099-1102.
27. Sollid L.M., Qiao S.W., Anderson R.P., Gianfrani C., Koning F. Nomenclature and listing of celiac disease relevant gluten T-cell epitopes restricted by HLA-DQ molecules. Immunogenetics 2012, 64:455-460.
28. Bergseng E., Sidney J., Sette A., Sollid L.M. Analysis of the binding of gluten T-cell epitopes to various human leukocyte antigen class II molecules. Hum Immunol 2008, 69:94-100.
29. Qiao S.W., Raki M., Gunnarsen K.S., Loset G.A., Lundin K.E., Sandlie I., et al. Posttranslational modification of gluten shapes TCR usage in celiac disease. J Immunol 2011, 187:3064-3071.
30. Vader W., Stepniak D., Kooy Y., Mearin L., Thompson A., van Rood J.J., et al. The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses. Proc Natl Acad Sci U S A 2003, 100:12390-12395.
31. De Re V., Simula M.P., Canzonieri V., Cannizzaro R. Proteomic analyses lead to a better understanding of celiac disease: focus on epitope recognition and autoantibodies. Dig Dis Sci 2010, 55:3041-3046.
32. Cornell H.J., Mothes T. The activity of wheat gliadin peptides in in vitro assays for coeliac disease. Biochim Biophys Acta 1993, 1181:169-173.
33. De Re V., Sansonno D., Simula M.P., Caggiari L., Gasparotto D., Fabris M., et al. HCV-NS3 and IgG-Fc crossreactive IgM in patients with type II mixed cryoglobulinemia and B-cell clonal proliferations. Leukemia 2006, 20:1145-1154.
34. Petersen N.H., Hansen P.R., Houen G. Fast and efficient characterization of an anti-gliadin monoclonal antibody epitope related to celiac disease using resin-bound peptides. J Immunol Methods 2011, 365:174-182.
35. Sulkanen S., Halttunen T., Laurila K., Kolho K.L., Korponay-Szabo I.R., Sarnesto A., et al. Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease. Gastroenterology 1998, 115:1322-1328.
36. Simon-Vecsei Z., Kiraly R., Bagossi P., Toth B., Dahlbom I., Caja S., et al. A single conformational transglutaminase 2 epitope contributed by three domains is critical for celiac antibody binding and effects. Proc Natl Acad Sci U S A 2012, 109:431-436.
37. Papista C., Berthelot L., Monteiro R.C. Dysfunctions of the Iga system: a common link between intestinal and renal diseases. Cell Mol Immunol 2011, 8:126-134.
38. Matysiak-Budnik T., Moura I.C., Arcos-Fajardo M., Lebreton C., Menard S., Candalh C., et al. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. J Exp Med 2008, 205:143-154.
39. Katoh S., Midorikami J., Takasu S., Ohkubo Y. Involvement of membrane-bound transglutaminase in the invagination of transferrin into rat reticulocyte plasma membrane. Biol Pharm Bull 1994, 17:1003-1007.
40. Halstensen T.S., Hvatum M., Scott H., Fausa O., Brandtzaeg P. Association of subepithelial deposition of activated complement and immunoglobulin G and M response to gluten in celiac disease. Gastroenterology 1992, 102:751-759.
41. Grant B.D., Donaldson J.G. Pathways and mechanisms of endocytic recycling. Nat Rev Mol Cell Biol 2009, 10:597-608.
42. Barone M.V., Nanayakkara M., Paolella G., Maglio M., Vitale V., Troiano R., et al. Gliadin peptide P31-43 localises to endocytic vesicles and interferes with their maturation. PLoS One 2010, 5:e12246.
43. Castellanos-Rubio A., Santin I., Martin-Pagola A., Irastorza I., Castano L., Vitoria J.C., et al. Long-term and acute effects of gliadin on small intestine of patients on potentially pathogenic networks in celiac disease. Autoimmunity 2010, 43:131-139.
44. Luciani A., Villella V.R., Vasaturo A., Giardino I., Pettoello-Mantovani M., Guido S., et al. Lysosomal accumulation of gliadin p31-43 peptide induces oxidative stress and tissue transglutaminase-mediated PPARgamma downregulation in intestinal epithelial cells and coeliac mucosa. Gut 2010, 59:311-319.
45. Panyam J., Zhou W.Z., Prabha S., Sahoo S.K., Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J 2002, 16:1217-1226.
46. Raiborg C., Bache K.G., Gillooly D.J., Madshus I.H., Stang E., Stenmark H. Hrs sorts ubiquitinated proteins into clathrin-coated microdomains of early endosomes. Nat Cell Biol 2002, 4:394-398.
47. Silano M., Vincentini O., Luciani A., Felli C., Caserta S., Esposito S., et al. Early tissue transglutaminase-mediated response underlies K562(S)-cell gliadin-dependent agglutination. Pediatr Res 2012, 71:532-538.
48. De Re V., Simula M.P., Notarpietro A., Canzonieri V., Cannizzaro R., Toffoli G. Do gliadin and tissue transglutaminase mediate PPAR downregulation in intestinal cells of patients with coeliac disease?. Gut 2010, 59:1730-1731.
49. Simula M.P., Cannizzaro R., Canzonieri V., Pavan A., Maiero S., Toffoli G., et al. PPAR signaling pathway and cancer-related proteins are involved in celiac disease-associated tissue damage. Mol Med 2010, 16:199-209.
50. Yousef M., Pichyangkura R., Soodvilai S., Chatsudthipong V., Muanprasat C. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action. Pharmacol Res 2012, 66:66-79.
51. Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev 2011, 91:151-175.
52. Fasano A. Zonulin, regulation of tight junctions, and autoimmune diseases. Ann N Y Acad Sci 2012, 1258:25-33.
53. Nistal E., Caminero A., Herr+ín A.R., Arias L., Vivas S., Ruiz De Morales J.M., et al. Differences of small intestinal bacteria populations in adults and children with/without celiac disease: effect of age, gluten diet, and disease. Inflamm Bowel Dis 2012, 18:649-656.
54. Sellitto M., Bai G., Serena G., Fricke W.F., Sturgeon C., Gajer P., et al. Proof of concept of microbiome-metabolome analysis and delayed gluten exposure on celiac disease autoimmunity in genetically at-risk infants. PLoS One 2012, 7.
55. Di Cagno R., De Angelis M., De Pasquale I., Ndagijimana M., Vernocchi P., Ricciuti P., et al. Duodenal and faecal microbiota of celiac children: molecular, phenotype and metabolome characterization. BMC Microbiol 2011, 11.
56. Rubio C.A. Lysozyme-rich mucus metaplasia in duodenal crypts supersedes Paneth cells in celiac disease. Virchows Arch 2011, 459:339-346.
57. Sanz Y., Pama G.D., Laparra M. Unraveling the ties between celiac disease and intestinal microbiota. Int Rev Immunol 2011, 30:207-218.
58. Gerritsen J., Smidt H., Rijkers G.T., De Vos W.M. Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr 2011, 6:209-240.
59. Bischoff S.C. 'Gut health': a new objective in medicine?. BMC Med 2011, 9.
60. Reid G., Younes J.A., Van Der Mei H.C., Gloor G.B., Knight R., Busscher H.J. Microbiota restoration: natural and supplemented recovery of human microbial communities. Nat Rev Microbiol 2011, 9:27-38.
61. Bernini P., Bertini I., Calabro A., La Marca G., Lami G., Luchinat C., et al. Are patients with potential celiac disease really potential? the answer of metabonomics. J Proteome Res 2011, 10:714-721.
62. Schippa S., Iebba V., Barbato M., Di Nardo G., Totino V., Checchi M.P., et al. A distinctive 'microbial signature' in celiac pediatric patients. BMC Microbiol 2010, 10.
63. Bertolazzi S., Lanzarotto F., Zanini B., Ricci C., Villanacci V., Lanzini A. Bio-physical characteristics of gastrointestinal mucosa of celiac patients: comparison with control subjects and effect of gluten free diet- BMC Gastroenterol 2011, 11:119.
64. Turner J.R. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 2009, 9:799-809.
65. Lammers K.M., Lu R., Brownley J., Lu B., Gerard C., Thomas K., et al. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology 2008, 135:194-204.
66. Schumann M, Kamel S, Pahlitzsch ML, Lebenheim L, May C, Krauss M, Hummel M, Daum S, Fromm M, Schulzke JD. Defective tight junctions in refractory celiac disease. Ann NY Acad Sci 1258[1], 43-51. 2012. Ref Type: Serial (Book, Monograph).
67. Thomas K.E., Sapone A., Fasano A., Vogel S.N. Gliadin stimulation of murine macrophage inflammatory gene expression and intestinal permeability are MyD88-dependent: role of the innate immune response in Celiac disease. J Immunol 2006, 176:2512-2521.
68. Lammers K.M., Khandelwal S., Chaudhry F., Kryszak D., Puppa E.L., Casolaro V., et al. Identification of a novel immunomodulatory gliadin peptide that causes interleukin-8 release in a chemokine receptor CXCR3-dependent manner only in patients with coeliac disease. Immunology 2011, 132:432-440.
69. Schumann M., Günzel D., Buergel N., Richter J.F., Troeger H., May C., et al. Cell polarity-determining proteins Par-3 and PP-1 are involved in epithelial tight junction defects in coeliac disease. Gut 2012, 61:220-228.
70. Barone M.V., Zanzi D., Maglio M., Nanayakkara M., Santagata S., Lania G., et al. Gliadin-mediated proliferation and innate immune activation in celiac disease are due to alterations in vesicular trafficking. PLoS One 2011, 6.
71. Trynka G., Hunt K.A., Bockett N.A., Romanos J., Mistry V., Szperl A., et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat Genet 2011, 43:1193-1201.
72. Dubois P.C., Trynka G., Franke L., Hunt K.A., Romanos J., Curtotti A., et al. Multiple common variants for celiac disease influencing immune gene expression. Nat Genet 2010, 42:295-302.
73. Hunt K.A., Zhernakova A., Turner G., Heap G.A., Franke L., Bruinenberg M., et al. Newly identified genetic risk variants for celiac disease related to the immune response. Nat Genet 2008, 40:395-402.
74. Smyth D.J., Plagnol V., Walker N.M., Cooper J.D., Downes K., Yang J.H., et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med 2008, 359:2767-2777.
75. de Kauwe A.L., Chen Z., Anderson R.P., Keech C.L., Price J.D., Wijburg O., et al. Resistance to celiac disease in humanized HLA-DR3-DQ2-transgenic mice expressing specific anti-gliadin CD4+ T cells. J Immunol 2009, 182:7440-7450.
76. Du Pre M.F., Kozijn A.E., van Berkel L.A., ter Borg M.N., Lindenbergh-Kortleve D., Jensen L.T., et al. Tolerance to ingested deamidated gliadin in mice is maintained by splenic, type 1 regulatory T cells. Gastroenterology 2011, 141:610-620.
77. Lees C.W., Barrett J.C., Parkes M., Satsangi J. New IBD genetics: common pathways with other diseases. Gut 2011, 60:1739-1753.
78. Kooy-Winkelaar Y., van Lummel M., Moustakas A.K., Schweizer J., Mearin M.L., Mulder C.J., et al. Gluten-specific T cells cross-react between HLA-DQ8 and the HLA-DQ2alpha/DQ8beta transdimer. J Immunol 2011, 187:5123-5129.
79. van Lummel M., van Veelen P.A., Zaldumbide A., de Ru A., Janssen G.M., Moustakas A.K., et al. Type 1 diabetes-associated HLA-DQ8 transdimer accommodates a unique peptide repertoire. J Biol Chem 2012, 287:9514-9524.
80. Caggiari L., Toffoli G., De R.V., Orzes N., Spina M., De Zorzi M., et al. KIR/HLA combination associated with the risk of complications in celiac disease. Int J Biol Markers 2011, 26:221-228.
81. Tack G.J., van Wanrooij R.L., Langerak A.W., Tjon J.M., von Blomberg B.M., Heideman D.A., et al. Origin and immunophenotype of aberrant IEL in RCDII patients. Mol Immunol 2012, 50:262-270.
82. Schmitz F., Tjon J.M., Lai Y., Thompson A., Kooy-Winkelaar Y., Lemmers R.J., et al. Identification of a potential physiological precursor of aberrant cells in refractory coeliac disease type II. Gut 2012.
83. Foxman E.F., Iwasaki A. Genome-virome interactions: examining the role of common viral infections in complex disease. Nat Rev Microbiol 2011, 9:254-264.
84. De Re V., Caggiari L., De Zorzi M., Toffoli G. KIR molecules: recent patents of interest for the diagnosis and treatment of several autoimmune diseases, chronic inflammation, and B-cell malignancies. Recent Pat DNA Gene Seq 2011, 5:169-174.
85. Malamut G., Meresse B., Cellier C., Cerf-Bensussan N. Celiac disease in 2009: a future without gluten-free diet?. Gastroenterol Clin Biol 2009, 33:635-647.
86. Pinier M., Fuhrmann G., Galipeau H.J., Rivard N., Murray J.A., David C.S., et al. The copolymer P(HEMA-co-SS) binds gluten and reduces immune response in gluten-sensitized mice and human tissues. Gastroenterology 2012, 142:316-325.
87. Huibregtse I.L., Marietta E.V., Rashtak S., Koning F., Rottiers P., David C.S., et al. Induction of antigen-specific tolerance by oral administration of Lactococcus lactis delivered immunodominant DQ8-restricted gliadin peptide in sensitized nonobese diabetic Abo Dq8 transgenic mice. J Immunol 2009, 183:2390-2396.
88. Gopalakrishnan S., Durai M., Kitchens K., Tamiz A.P., Somerville R., Ginski M., et al. Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides 2012, 35:86-94.
89. Arrieta M.C., Madsen K., Doyle J., Meddings J. Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse. Gut 2009, 58:41-48.
90. Laparra J.M., Olivares M., Gallina O., Sanz Y. Bifidobacterium longum CECT 7347 modulates immune responses in a gliadin-induced enteropathy animal model. PLoS One 2012, 7:e30744.